No Prescription |
 |
 | ||
|
ODIVIR Sustiva |
|
| ||
No Prescription » Prescription Drugs 12 » ODIVIR Sustiva Antiretroviral.Odivir is used in the treatment of the infection caused by the human immunodeficiency virus (HIV). HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Odivir is an antiviral medication that prevents human immunodeficiency virus (HIV) cells from multiplying in your body.Odivir is used to treat HIV which causes the acquired immunodeficiency syndrome (AIDS). Odivir is not a cure for HIV or AIDS. Buy ODIVIR Sustiva and other Prescription Drugs 12 products online at Medstore. 3981
About ODIVIR Sustiva: Product Type: Prescription Drugs 12 ODIVIR ( Sustiva Epivir Combivir Videx Generic Efavirenz/Lamivudine/Didanosine ) ODIVIR (Sustiva Epivir Combivir Videx Generic Efavirenz/Lamivudine/Didanosine) Sustiva Epivir Combivir Videx Generic Efavirenz/Lamivudine/Didanosine 600/300/250mg Kit ( 10 foils ) Sustiva Epivir Combivir Videx Generic Efavirenz/Lamivudine/Didanosine ODIVIR
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
